

FINANCIAL UPDATE

BOARD MEETING

Assietou Diouf

22-23 June 2022, Geneva, Switzerland



Reach every child

www.gavi.org

Gavi 2021 Financial Performance

Gavi 5.0 at 97% and COVAX AMC at 88% of forecasted expenditure

Gavi 5.0 US\$ million, cash flow basis	2021 Forecast	2021 Actual	
		US\$ million	% of the Forecast
Qualifying Resources	\$ 1,923	\$ 1,639	85%
Expenditure	\$ 1,955	\$ 1,892	97%


- Lower inflows driven principally by slight delay in contributions received early 2022 (US\$ -284 m).
- Expenditures at 97% of the 2021 forecast (US\$ -62 m)
 - Routine immunisation coverage mainly maintained
 - HSIS and PEF : different degree of disruption to routine immunisation services due to COVID-19.

COVAX AMC US\$ million, cash flow basis	2021 Forecast	2021 Actual	
		US\$ million	% of the Forecast
Qualifying Resources	\$ 10,299	\$ 9,158	89%
Expenditure	\$ 8,510	\$ 7,480	88%

- Inflows impacted by deferred cash-in from Q4 2021 to Q1 2022 (US\$ -1,141 m)
- Lower expenditures at 88% than expected - driven by rephasing of forecast to reflect vaccine supply context (US\$ -1,030 m).


Gavi 5.0: no material changes to the financial forecast

US\$ million, cash flow basis	Gavi 5.0 Dec 2021 Forecast v19.0	Gavi 5.0 Jun 2022 Forecast v19.1
Qualifying Resources	\$ 10,764	\$ 10,681
Forecast Expenditures	\$ 10,452	\$ 10,384
<i>Decision for consideration: Innovation Approach</i>		\$ 50
Net available for future investments	\$ 312	\$ 247



COVAX AMC: updated forecast reflecting the new commitments made at the Break Covid Now Summit

US\$ million, cash flow basis	2020-2023 Dec 2021 Forecast	2020-2023 Jun 2022 Forecast
Qualifying Resources	\$ 10,828	\$ 12,265
Forecast Expenditures	\$ 10,655	\$ 12,066
Costs Sharing Backshop	\$ 79	\$ 22
Net available for future investments	\$ 94	\$ 178



Consolidated view of Gavi 5.0 (2021-2025) and initial outlook of 6.0 ⁽¹⁾ (2026-2030)

US\$ million, cash flow basis	Gavi 5.0 (v19.1)	COVAX AMC 2020-2023	Consolidated Gavi 5.0 & COVAX AMC
Qualifying Resources	\$ 10,681	\$ 12,265	\$ 22,946
Forecast Expenditure	\$ 10,434	\$ 12,088*	\$ 22,521
Net available for future investments	\$ 247	\$ 178	\$ 425

* Includes \$ 22m Cost Sharing Backshop

- US\$ 22.9 billion Qualifying resources
- Allocated to programmatic initiatives under **GAVI 5.0** and **COVAX AMC**
- Net available for future investments **US\$ 425 million**

US\$ million, cash flow basis	Gavi 6.0 2026-2030
Qualifying Resources	\$ 8,805
Forecast Expenditure	\$ 7,809
Net available for future investments	\$ 995

(1) Core only – excludes projections on Covax

Key Risks and Opportunities to the Financial Forecast

	Risk	Mitigation
Gavi 5.0	Disruption caused by COVID 19 on immunisation programmes.	Continuous engagement with countries & partners to remain agile and phase programs.
	Ukraine/Russia conflict: risk to supply, high inflation, donor funding reprioritisation.	Gavi is engaging with partners to mitigate any potential supply disruption through diversification.
	Economic Outlook is negative: FX volatility may impact Gavi's returns on invested portfolio, potential domestic fiscal pressure in implementing countries.	Significant progress has been made in concluding the majority of the donor agreements thereby reducing FX exposure. The Secretariat is finalising the remaining agreements
COVAX AMC	Uncertain trajectory of the pandemic.	Ability to respond to WHO pandemic scenario.
	Lower demand from countries to buy vaccines	Rightsizing supply - Ongoing negotiations with COVID-19 manufacturers on Firm Order Commitments.

Recommendation

The Gavi Alliance Audit and Finance Committee **recommends** to the Gavi Alliance Board that it:

- a) **Note** that the Audit and Finance Committee reviewed the financial implications of the recommendation to be made to the Programme and Policy Committee and concluded that the recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy;
- b) **Approve** the updated Financial Forecast for the Gavi 5.0 (2021-2025) Strategic Period as set out in Section 2 and Annex B to Doc 04;
- c) **Approve** the updated Financial Forecast for COVAX AMC (2020-2023) as set out in Section 3 and Annex D to Doc 04; and
- d) **Approve** the Financial Forecast for the Gavi 6.0 (2026-2030) Strategic Period noting that only existing programmes have been forecast and the forecast has been prepared to enable the Secretariat to allot funding to these programmes in accordance with the Programme Funding Policy and does not prejudge future donor contributions or future investment decisions.

THANK YOU



Reach every child

www.gavi.org